All In Biotech

Drug Trial Radar · NCT07766317

Autologous Tumor Infiltrating Lymphocyte (TIL) GT201 Infusion.

A Phase I/II Open-Label Clinical Study of Autologous Tumor Infiltrating Lymphocyte Infusion (GT201) in the Treatment of Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

63

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Jun 2030

Study completion Jun 2032

Sponsor

Lead sponsor
Gritbio Medicine, Inc.Industry
Sponsor type
Industry
First posted
Aug 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, single-arm phase 1/2 clinical trial to evaluate the safety and tolerability of GT201 as a monotherapy or in combination with anti-PD-1 therapy in patients with advanced solid tumors, and to evaluate the efficacy of this therapy.

Conditions

  • Advanced Solid Tumors Cancer

Interventions

  • GT201Biological

    A tumor sample from individual participant is collected through a surgical resection for ex vivo manufacturing of GT201 TIL cell product.

  • IL-2 and PD-1Biological

    Participants tandemly receives a lymphodepleting regimen, GT201 TIL product, and IL-2. Some participants may also receive a PD-1 inhibitor following GT201 infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the safety of GT201 in the treatment of recurrent or metastatic solid tumorsTime frame: Upto 2 years
  2. To assess the safety of GT201 in the treatment of recurrent or metastatic solid tumorsTime frame: Upto 2 years
  3. To assess the tolerance of GT201 and decide on the recommended Phase 2 dose.Time frame: Upto 2 years
  4. To assess the Objective Response Rate (ORR) of GT201 infusion in accordance with RECIST v1.1Time frame: Upto 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.